Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ally Financial

Blindly selecting Buffett stocks for your portfolio is probably a bad idea, but buying Buffett stocks that have track records of dividend growth greatly boosts your odds of outperforming the market. Ally Financial is an all-digital bank that pays a big 4.5% dividend yield at its current share price.

2 Buffett Stocks With Above-Average Dividend Yields to Buy Now

J&J's unpopular Covid vaccine appeared to bear its last fruit during the first quarter, contributing $747 million in sales.

Johnson & Johnson expects no new Covid vaccine revenue, after shots drive earnings beat

Johnson and Johnson  JNJ  reported Q1 2023 earnings on Tuesday, April 18 before the market opened. The report showed strong top and bottom-line growth, and with the reasonable valuation JNJ currently maintains, it demonstrates some very appealing characteristics.

Johnson and Johnson Beats Estimates and Raises Guidance

Johnson & Johnson's Dividend: 61 And Counting

J&J reported better-than-expected 2023 Q1 financial results ahead of the opening bell this morning. Nonetheless, investors are taking a cautious approach with the healthcare giant over its talcum-powder litigation.

Why Johnson & Johnson Stock Is Slumping Today

Goldman Sachs

Shares of Johnson & Johnson JNJ, -2.36% and Goldman Sachs Group Inc. GS, -1.84% were the biggest drags on the Dow Jones Industrial Average DJIA, -0.03% , even as both companies reported first-quarter profit that topped expectations. J&J's stock fell $3.92, or 2.4%, as the drug maker recorded a large charge as it settled lawsuits stemming from its talc-containing powders.

J&J, Goldman stocks cut Dow's price by 68 points after earnings

Bank of America

Fresh Q1 earnings reports from major household firms join housing data from last month ahead of today's open.

Housing Data Muted but Decent; JNJ and BAC Beat on Q1 Earnings

J&J (JNJ) beats estimates for first-quarter earnings and sales. It raises full-year sales and earnings guidance.

J&J (JNJ) Q1 Earnings & Sales Top, 2023 View Up, Stock Rises

Johnson & Johnson (JNJ) Q1 2023 Earnings Call Transcript

Shares of Johnson & Johnson (NYSE: JNJ) opened down this morning after the consumer health and pharmaceutical company said it swung to a loss in its first financial quarter. What resulted in a loss this quarter?

J&J Q1 earnings: ‘we feel very good about 2023'

While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Johnson & Johnson (JNJ) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

Johnson & Johnson (NYSE:JNJ) has credited a positive start to its 2023 financial year to strong performances from its three business segments as it raised its full-year guidance.  However, the healthcare giant swung to a first-quarter loss after it accounted for a special one-time charge of $6.9 billion after subsidiary LTL Management re-filed for voluntary Chapter 11 bankruptcy protection and J&J agreed to contribute $8.9 billion, over 25 years, to settle thousands of lawsuits related to its baby powder and talc products, up from $2 billion previously.

Johnson & Johnson raises full-year guidance as it puts talc lawsuit claims behind it

Johnson & Johnson (JNJ) came out with quarterly earnings of $2.68 per share, beating the Zacks Consensus Estimate of $2.51 per share. This compares to earnings of $2.67 per share a year ago.

Johnson & Johnson (JNJ) Q1 Earnings and Revenues Top Estimates

Johnson & Johnson beat first-quarter expectations Tuesday and raised its full-year outlook. In response, JNJ stock edged higher.

J&J Stock Closes In On A Key Point After Quarterly Beat And Raise

Cigna

CVS Health

Chevron

First Republic

Home Depot

Pfizer

Charles Schwab

UnitedHealth Group

What's worse than missing out on the five stocks driving the entire S&P 500 this year? Owning the ones that are dragging it down.

These 10 Crummy Stocks Already Cost Investors $300 Billion

First-quarter earnings were wiped out by a $6.9 billion charge tied to litigation and other costs from its Covid-19 vaccine commitments.

Johnson & Johnson Posts Higher Quarterly Sales, Raises 2023 Outlook

J&J, whose financial results are considered a bellwether for many health companies, said its first-quarter sales grew 5.6% over the same quarter last year.

Johnson & Johnson beats on earnings and revenue, raises full-year guidance

Medical Properties Trust

Companies in getting sued by customers are the dividend stocks to avoid. Shareholders who sue the company are less serious.

3 Dividend Stocks to Sell Before They Get Sued by Customers

Johnson & Johnson's stock JNJ, -0.10% rose 1.4% in premarket trade Tuesday, after the consumer health and pharma company beat consensus estimates for its first quarter and raised its full-year guidance. The company had a loss of $68 million, or 3 cents a share, for the quarter, after income of $5.149 billion, or $1.93 a share, in the year-earlier period.

Johnson & Johnson beats Q1 consensus estimates and raises guidance

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2023. “Our first quarter results demonstrate strong performance across all three segments of our business and reflect the dedication of Johnson & Johnson colleagues around the world,” said Joaquin Duato, Chairman of the Board and Chief Executive Officer.

Johnson & Johnson Reports Q1 2023 Results

A Johnson & Johnson subsidiary is again asking a U.S. judge to pause tens of thousands of lawsuits alleging that the company's baby powder and other talc products cause cancer, as it takes another shot at resolving the litigation in bankruptcy after a federal appeals court found its first attempt improper.

J&J talc unit again seeks to halt 38,000 cancer lawsuits

Dollar General

Vertex Pharmaceuticals

Dollar General is arguably the ultimate recession-proof stock. Johnson & Johnson is a favorite safe-haven stock for investors during economic downturns.

The Fed Thinks a Recession Is More Likely: Here Are 3 Great Stocks to Buy Now

Apple

AbbVie

Bristol-Myers

Deere & Company

JPMorgan Chase & Co

Mastercard

Mercedes-Benz Group AG

Altria

Microsoft

Schwab US Dividend Equity ETF

Suncor Energy

Toronto-Dominion Bank

Taiwan Semiconductor Manufacturing

TotalEnergies SE

U.S. Bancorp

Visa

Verizon

In this article, I will show you how you could allocate $10,000 among my top 20 dividend growth and high dividend yield companies for the month of April. Due to the allocation I have chosen, that I'll discuss in this article, you would achieve a Weighted Average Dividend Yield [FWD] of 3.12% with this portfolio.

How To Allocate $10,000 Among My Top 20 Dividend Stocks Of April 2023

Johnson & Johnson JNJ continues to work on strengthening its Pharma segment, which has been driving revenues over the past few quarters. In J&J's Pharma segment, its oncology drug, Darzalex as well as psoriasis treatment, Stelara are likely to have driven sales growth in the first quarter due to increased penetration and new indications.

Will J&J (JNJ) Pharma Unit Outperform Market & Drive Q1 Results?

The $8.9 billion talcum-powder settlement agreement isn't final, but it's progress. Johnson & Johnson can easily afford its litigation costs.

News for Johnson & Johnson Stock (JNJ)